학술논문
Impaired resolution of blood transcriptomes through tuberculosis treatment with diabetes comorbidity
Document Type
article
Author
Clare Eckold; Cassandra L. R. vanDoorn; Rovina Ruslami; Katharina Ronacher; Anca‐Lelia Riza; Suzanne vanVeen; Ji‐Sook Lee; Vinod Kumar; Sarah Kerry‐Barnard; Stephanus T. Malherbe; Léanie Kleynhans; Kim Stanley; Simone A. Joosten; Julia A Critchley; Philip C. Hill; Reinout vanCrevel; Cisca Wijmenga; Mariëlle C. Haks; Mihai Ioana; Bachti Alisjahbana; Gerhard Walzl; Tom H. M. Ottenhoff; Hazel M. Dockrell; Eleonora Vianello; Jacqueline M. Cliff; the TANDEM Consortium$
Source
Clinical and Translational Medicine, Vol 13, Iss 9, Pp n/a-n/a (2023)
Subject
Language
English
ISSN
2001-1326
Abstract
Abstract Background People with diabetes are more likely to develop tuberculosis (TB) and to have poor TB‐treatment outcomes than those without. We previously showed that blood transcriptomes in people with TB‐diabetes (TB‐DM) co‐morbidity have excessive inflammatory and reduced interferon responses at diagnosis. It is unknown whether this persists through treatment and contributes to the adverse outcomes. Methods Pulmonary TB patients recruited in South Africa, Indonesia and Romania were classified as having TB‐DM, TB with prediabetes, TB‐related hyperglycaemia or TB‐only, based on glycated haemoglobin concentration at TB diagnosis and after 6 months of TB treatment. Gene expression in blood at diagnosis and intervals throughout treatment was measured by unbiased RNA‐Seq and targeted Multiplex Ligation‐dependent Probe Amplification. Transcriptomic data were analysed by longitudinal mixed‐model regression to identify whether genes were differentially expressed between clinical groups through time. Predictive models of TB‐treatment response across groups were developed and cross‐tested. Results Gene expression differed between TB and TB‐DM patients at diagnosis and was modulated by TB treatment in all clinical groups but to different extents, such that differences remained in TB‐DM relative to TB‐only throughout. Expression of some genes increased through TB treatment, whereas others decreased: some were persistently more highly expressed in TB‐DM and others in TB‐only patients. Genes involved in innate immune responses, anti‐microbial immunity and inflammation were significantly upregulated in people with TB‐DM throughout treatment. The overall pattern of change was similar across clinical groups irrespective of diabetes status, permitting models predictive of TB treatment to be developed. Conclusions Exacerbated transcriptome changes in TB‐DM take longer to resolve during TB treatment, meaning they remain different from those in uncomplicated TB after treatment completion. This may indicate a prolonged inflammatory response in TB‐DM, requiring prolonged treatment or host‐directed therapy for complete cure. Development of transcriptome‐based biomarker signatures of TB‐treatment response should include people with diabetes for use across populations.